The estimated Net Worth of R Matthew Neff is at least $992 Thousand dollars as of 19 August 2020. Mr. Neff owns over 5,000 units of Basis Global Technologies Inc stock worth over $992,154 and over the last 7 years he sold BASI stock worth over $0. In addition, he makes $0 as Independent Director at Basis Global Technologies Inc.
Sign up
Mr. Neff BASI stock SEC Form 4 insiders trading
R has made over 8 trades of the Basis Global Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BASI stock worth $23,750 on 19 August 2020.
The largest trade he's ever made was buying 15,350 units of Basis Global Technologies Inc stock on 12 March 2020 worth over $58,791. On average, R trades about 4,494 units every 100 days since 2017. As of 19 August 2020 he still owns at least 60,350 units of Basis Global Technologies Inc stock.
You can see the complete history of Mr. Neff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
R. Matthew Neff biography
R. Matthew Neff is an Independent Director of the Company. Mr. Neff is currently Of Counsel with Bingham Greenebaum Doll LLP’s Corporate and Transactional Department. From August 2013 through June 2016, Mr. Neff served as Chairman, President and Chief Executive Officer of AIT Laboratories, a national toxicology lab headquartered in Indianapolis, Indiana. Mr. Neff joined AIT Laboratories after his tenure as President and Chief Executive Officer of CHV Capital, Inc., the venture capital subsidiary of Indiana University Health, a role he had held since 2007. Mr. Neff started his career as a practicing lawyer and Partner at Baker & Daniels. He then served as the Deputy to the Chairman of the Federal Housing Finance Board (now known as the Federal Housing Finance Agency) in the first Bush Administration. Thereafter, he became the co-founder and Chief Executive Officer of two Indianapolis companies: Circle Investors, an insurance holding company then chaired by former Vice President of the United States, Dan Quayle, and Senex Financial Corp., a healthcare receivables finance company. Mr. Neff currently serves on the Board of Directors of Fairbanks Addiction Treatment Center and was a member of Riley Children’s Foundation’s Board of Directors from January 2000 to November 2012. Mr. Neff earned his bachelor’s degree and graduated a Phi Beta Kappa from DePauw University. He also received his Juris Doctor degree from Indiana University School of Law, where he was the Executive Editor of the Indiana Law Review.
What's R Neff's mailing address?
R's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906-1382.
Insiders trading at Basis Global Technologies Inc
Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure, and William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.
What does Basis Global Technologies Inc's logo look like?
Complete history of Mr. Neff stock trades at Basis Global Technologies Inc
Basis Global Technologies Inc executives and stock owners
Basis Global Technologies Inc executives and other stock owners filed with the SEC include:
-
Wendy Perrow,
Independent Director -
R. Matthew Neff,
Independent Director -
Richard Johnson,
Independent Director -
Joseph Flynn,
Chief Commercial Officer -
John Sagartz,
Chief Strategy Officer, Director -
Connie Dougherty,
Vice President - Business Development -
I.M. Grossi,
Vice President - Toxicology -
Philip Downing,
Vice President - Preclinical Services -
Andrew Alexander,
Vice President - Pharmacology and Toxicology Operations -
Michael Baim,
Vice President - Bioanalytical Operations -
Beth Taylor,
Chief Financial Officer, Vice President - Finance -
Robert Leasure,
President, Chief Executive Officer, Director -
Gregory Davis,
Interim Chairman of the Board -
Jill Blumhoff,
VP, Finance & CFO -
John P Devine,
VP--Toxicology -
James Sevall Bourdage,
VP, Bioanalytical Services -
Jacqueline M Lemke,
CFO & Vice President--Finance -
Jeffrey Potrzebowski,
VP, Finance & CFO -
John Gregory Beattie,
Chief Operating Officer -
Peterkissinger Candice B Ki...,
-
Daniel Thomas Oakley,
Chief Operating Officer -
Kimberly L Sagartz,
10% owner -
Chrysalis, Llc Sw,
10% owner -
Lori Payne,
VP Bioanalytical Services -
Larry Steven Boulet,
Director -
David W Crabb,
Director -
John B. Landis,
Director -
David L Omachinski,
Director -
Anthony S Chilton,
COO, Scientific Studies -
A. Charlene Sullivan,
Director -
Alberto F Jr Hidalgo,
VP, Bus. Development & Mrkting -
Leslie B Daniels,
Director -
Kathleen Hodges,
Vice President of Quality -
Lina L Reeves Kerner,
V.P. - Human Resources -
Richard M Shepperd,
President & Chief Exec. Off. -
Ronald E Shoup,
Chief Operating Officer -
Craig S Bruntlett,
Sr. V.P. International Sales -
Jon Brewer,
VP Sales/Marketing -
William E Baitinger,
Director -
Candice B Kissinger,
Vice President -
Margaret B Mcclure,
Dir, Pharmaceutical Lab. Div. -
Michael R Cox,
V.P. Finance, CFO -
Emilio Cordova,
V.P. of Business Development -
Edward Chait,
Executive Vice President -
Gerry Henningsen,
Director BAS Evansville -
Donnie A Evans,
Vice President Engineering -
Garyl W Doster,
Director -
Michael P Silvon,
Vice President -
Michael S Noone,
Dir. of Clinical Affairs, Balt -
William Sawyers,
Laboratory Director -
William D Pitchford,
Chief HR Officer